Publications by authors named "Avivit Shoham"

Introduction: 18-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is a well-established tool for managing metastatic infections. Nocardiosis, a primarily pulmonary infection, disseminates at high rates. Routine imaging includes chest CT and brain imaging.

View Article and Find Full Text PDF

Midostaurin is a tyrosine multikinase inhibitor approved for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with mutated Fms-like tyrosine kinase-3. We describe a case report of a 49-year-old AML patient treated with an intensive chemotherapy regimen followed by midostaurin. After achieving complete remission with blood count recovery, he suffered from a serious, rare complication of necrotizing hemorrhagic gastritis with no evidence of infection or malignant infiltration, possibly associated with midostaurin therapy.

View Article and Find Full Text PDF

Unlabelled: Death rates from hepatocellular carcinoma (HCC) are steadily increasing, yet therapeutic options for advanced HCC are limited. We identify a subset of mouse and human HCCs harboring VEGFA genomic amplification, displaying distinct biologic characteristics. Unlike common tumor amplifications, this one seems to work via heterotypic paracrine interactions; stromal VEGF receptors (VEGFR), responding to tumor VEGF-A, produce hepatocyte growth factor (HGF) that reciprocally affects tumor cells.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Avivit Shoham"

  • - Avivit Shoham's research primarily explores the use of advanced imaging techniques such as FDG-PET/CT to improve the management of complicated infections like nocardiosis, illuminating the significance of comprehensive imaging in conditions characterized by high dissemination rates.
  • - Shoham also investigates unexpected complications arising from cancer treatments, such as a case involving necrotizing hemorrhagic gastritis following the administration of midostaurin in acute myeloid leukemia patients, emphasizing the need for awareness of rare treatment-related effects.
  • - Additionally, research into hepatocellular carcinoma (HCC) identifies the sensitivity of VEGFA-amplified tumors to sorafenib, demonstrating the potential for targeted therapies based on specific genomic alterations within tumors.